ADAMTS-7 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-ADAMTS7
In stock
- SKU
- REC-ADAMTS7
Target Overview
ADAMTS-7 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 7; UniProt Q9UKP4) is a secreted, extracellular matrix-associated zinc metalloprotease encoded by the ADAMTS7 gene. The full-length human protein spans 1,686 amino acids and belongs to the ADAMTS family, which is characterised by a reprolysin-type metalloprotease domain, disintegrin-like domain, and one or more C-terminal thrombospondin type-1 repeats. This recombinant is produced in HEK293 mammalian cells, an expression system that supports the post-translational processing — including glycosylation and propeptide removal — expected for a secreted protease of this class. The catalytic classification of ADAMTS-7 carries EC 3.4.24.- (metalloendopeptidase) designation. Its substrate scope has been the subject of active investigation: an early study attributed cartilage oligomeric matrix protein (COMP) cleavage to ADAMTS-7, earning it the informal name "COMPase," but a more recent report (PubMed:39672391) found no detectable activity against COMP under the tested conditions, underscoring the need for carefully controlled in vitro assays to define substrate specificity. In the laboratory, recombinant ADAMTS-7 is used as an enzymatic reagent for substrate cleavage studies using fluorogenic or native ECM substrates, for inhibitor IC50 determinations in small-molecule screening campaigns, and as a reference standard in activity assays where a defined, active metalloprotease is required. Researchers running Western blot or immunoprecipitation validation experiments can pair this recombinant with Triple Point Biologics' matched antibody (SKU: RP-ADAMTS7) as a verified positive control, ensuring the antibody signal corresponds to the correct molecular weight and form of ADAMTS-7.
Background
Applications
- Metalloprotease activity assay using fluorogenic peptide substrates to define cleavage kinetics (Km, kcat)
- Inhibitor IC50 determination for small-molecule ADAMTS-7 inhibitors (e.g., BAY-9835 class compounds) in biochemical format
- Substrate identification and profiling by mass spectrometry-based degradomics
- ECM substrate cleavage assay with native extracellular matrix components to characterise specificity
- Antibody validation positive control for Western blot and immunoprecipitation when paired with Triple Point Biologics antibody RP-ADAMTS7
- Enzyme-linked binding assay to characterise protein–protein interactions with ADAMTS-7 binding partners
- SPR or BLI biophysical binding assay to determine inhibitor or substrate Kd values against immobilised recombinant ADAMTS-7
References
- Goyal S et al. The biology and pathophysiology of the proatherogenic metalloprotease ADAMTS7. Open Biol. 2026. doi:10.1098/rsob.250111. PMID: 41920022.
- Ling Y et al. ADAMTS7 selective inhibitor BAY-9835 alleviates acute myocardial infarction by suppressing the NF-κB-mediated pyroptosis. Toxicol Appl Pharmacol. 2026. doi:10.1016/j.taap.2026.117836. PMID: 42061659.
- Xu Y et al. ADAMTS-7 Increase Contributes to Worsened Neurological Outcome in Mice on High Fat Diet. CNS Neurosci Ther. 2026. doi:10.1002/cns.70877. PMID: 41968389.
- Chen L et al. A functional polymorphism in ADAMTS7 3'-UTR abrogates miR-654-5p-mediated ADAMTS7 expression suppression and increases the incidence, short-term outcome, and recurrence of large artery atherosclerotic stroke among southern Chinese population. Artif Cells Nanomed Biotechnol. 2026. doi:10.1080/21691401.2026.2670966. PMID: 42184821.
- Morgan D et al. Role of molecular driver mutations in recurrence of early-stage laryngeal cancer following narrow field definitive radiotherapy. Oral Oncol Rep. 2026. doi:10.1016/j.oor.2025.100780. PMID: 42125265.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Secreted; Extracellular matrix |
Frequently Asked Questions
What molecular weight band should I expect for recombinant ADAMTS-7 on SDS-PAGE or Western blot?
The full-length human ADAMTS-7 protein (UniProt Q9UKP4) has a predicted molecular weight of ~188 kDa from its 1,686 amino acid sequence, but the HEK293-expressed recombinant runs noticeably higher on SDS-PAGE — typically in the 200–220 kDa range — due to N- and O-linked glycosylation added during mammalian cell processing. Purity is >95% by SDS-PAGE. If you are using our matched rabbit polyclonal antibody (RP-ADAMTS7), this glycosylated band is what you should set as your positive control reference point.
Does recombinant ADAMTS-7 from HEK293 cells include the propeptide or is it the processed mature form?
HEK293 cells support propeptide removal through furin-like convertase activity in the secretory pathway, so the recombinant ADAMTS-7 supplied here is the processed, mature form with the prodomain cleaved. This is the enzymatically active species. If your experimental design specifically requires the zymogen form or a defined propeptide-containing construct, this product is not suitable and you would need to engineer the furin site. For most protease activity and substrate cleavage studies, the processed form is the relevant species.
Does recombinant ADAMTS-7 cleave COMP (cartilage oligomeric matrix protein) and what substrates are validated?
ADAMTS-7 was originally described as a COMPase, but a 2024 report (PubMed:39672391) found no detectable COMP cleavage under controlled conditions, raising questions about substrate specificity. This remains an active area of investigation, so interpret any COMP cleavage data cautiously and include appropriate controls. For activity assays, fluorogenic peptide substrates based on aggrecan cleavage sites (TEGE↓ARGS motif) or generic metalloprotease substrates such as Mca-RPLALWRS-Dpa-NH2 can be used as functional readouts, though substrate selectivity data specific to ADAMTS-7 should be interpreted in the context of your biological system.
What buffer conditions are recommended for an ADAMTS-7 activity assay?
The storage buffer for this recombinant is 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 5 mM CaCl2 — the calcium is included because ADAMTS family metalloproteases require Ca²⁺ for catalytic stability. For activity assays, a compatible assay buffer would be 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, with 0.05% Brij-35 added to reduce non-specific surface adsorption at low enzyme concentrations. Avoid EDTA or EGTA, which will chelate Zn²⁺ and Ca²⁺ and abolish activity. Confirm Zn²⁺ is not depleted in your substrate buffer.
What starting concentration of recombinant ADAMTS-7 should I use for a fluorogenic peptide cleavage assay?
A reasonable starting point for fluorogenic substrate assays is 10–50 nM enzyme with substrate concentrations ranging from 5–100 µM, giving a substrate-to-Km range suitable for initial velocity measurements. Because ADAMTS-7's kinetic parameters against most peptide substrates are not yet precisely defined in the literature, we recommend a concentration–response titration (1, 5, 10, 25, 50 nM enzyme) before committing to a fixed concentration. Incubate at 37°C and read fluorescence (ex/em ~320/405 nm for Mca-based substrates) at 5-minute intervals over 60–120 minutes to capture linear velocity.
Can I use recombinant ADAMTS-7 as a Western blot positive control with the RP-ADAMTS7 rabbit polyclonal antibody?
Yes — this is the primary use case for pairing REC-ADAMTS7 with RP-ADAMTS7. The rabbit polyclonal antibody (RP-ADAMTS7) was validated against the same HEK293-expressed recombinant, so band identity is confirmed. Load 20–50 ng of REC-ADAMTS7 per lane alongside your cell lysate samples. Expect a band at ~200–220 kDa under denaturing, non-reducing conditions. Reducing conditions should give a similar band since ADAMTS-7 does not rely on inter-chain disulfides for its primary structure. The matched pair removes ambiguity when interpreting endogenous ADAMTS-7 bands in tissue or cell lysates.
How much recombinant ADAMTS-7 should I load as a positive control and what dilution of RP-ADAMTS7 antibody should I use?
Load 20–50 ng of REC-ADAMTS7 per lane for a clean, unambiguous positive control signal on Western blot. For the matched RP-ADAMTS7 rabbit polyclonal antibody, a primary antibody dilution of 1:500–1:2,000 in 5% BSA/TBST is a practical starting range; optimize based on your secondary antibody and detection system. The antibody has been validated for Western blot, so these parameters reflect empirically determined working ranges. For IHC, RP-ADAMTS7 is also validated — refer to the antibody product page at /anti-adamts-7-rabbit-polyclonal-antibody for tissue-specific staining protocols.
How should I store and handle recombinant ADAMTS-7 to preserve enzymatic activity long term?
REC-ADAMTS7 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 and shipped on dry ice. Upon receipt, aliquot immediately into single-use volumes to avoid repeated freeze-thaw cycles, which degrade metalloprotease activity. Store at -20°C; do not store at 4°C long-term. When thawing for an assay, place the aliquot on ice and use within the same working session. Do not add additional EDTA or metal chelators to working dilutions. Properly stored, activity is stable for at least 12 months from the date of manufacture when freeze-thaw is avoided.
Validation imagery coming soon
Western blot validation figures for REC-ADAMTS7 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.